Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Triasima Portfolio Management inc.

Triasima Portfolio Management inc. trimmed its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 0.7% in the second quarter, HoldingsChannel.com reports. The firm owned 7,567 shares of the biotechnology company’s stock after selling 52 shares during the quarter. Triasima Portfolio Management inc.’s holdings in Axon Enterprise were worth $2,227,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Blue Trust Inc. boosted its holdings in shares of Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 79 shares in the last quarter. ICA Group Wealth Management LLC purchased a new stake in Axon Enterprise in the fourth quarter valued at $26,000. Trivant Custom Portfolio Group LLC purchased a new position in shares of Axon Enterprise during the first quarter worth about $31,000. First PREMIER Bank purchased a new position in shares of Axon Enterprise during the first quarter worth about $33,000. Finally, Blue Bell Private Wealth Management LLC acquired a new stake in shares of Axon Enterprise during the first quarter worth about $41,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Stock Performance

Shares of AXON stock traded down $0.24 during trading hours on Friday, reaching $354.62. 509,150 shares of the company’s stock were exchanged, compared to its average volume of 514,277. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company’s 50 day moving average is $331.40 and its two-hundred day moving average is $311.15. The company has a market cap of $26.76 billion, a P/E ratio of 103.69, a price-to-earnings-growth ratio of 9.52 and a beta of 0.94. Axon Enterprise, Inc. has a 1 year low of $189.12 and a 1 year high of $378.89.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. During the same quarter last year, the company earned $0.80 earnings per share. Axon Enterprise’s quarterly revenue was up 34.5% compared to the same quarter last year. Equities research analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the sale, the chief executive officer now owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Patrick W. Smith sold 80,300 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the transaction, the chief executive officer now owns 3,015,366 shares in the company, valued at $1,121,052,771.48. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the completion of the sale, the director now owns 7,379 shares in the company, valued at $2,752,588.37. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 278,650 shares of company stock valued at $101,364,745. Corporate insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AXON shares. JMP Securities reissued a “market outperform” rating and issued a $375.00 target price on shares of Axon Enterprise in a report on Wednesday, August 7th. Northland Securities raised their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Robert W. Baird raised their target price on shares of Axon Enterprise from $355.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research note on Wednesday, August 7th. Finally, Barclays raised their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $358.08.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.